

META HEALTH LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 198804700N)

PROPOSED RENOUNCEABLE NON-UNDERWRITTEN RIGHTS ISSUE OF UP TO 518,066,109 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY AT A RIGHTS ISSUE PRICE OF S\$0.0055 FOR EACH RIGHTS SHARE ON THE BASIS OF NINE (9) RIGHTS SHARES FOR EVERY TEN (10) EXISTING ORDINARY SHARES IN THE CAPITAL OF THE COMPANY HELD BY EACH SHAREHOLDER OF THE COMPANY AS AT THE RECORD DATE, FRACTIONAL ENTITLEMENTS TO BE DISREGARDED

- NOTICE OF RECORD DATE

1. INTRODUCTION

- 1.1. The board of directors (the “**Board**”) of Meta Health Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the Company’s announcements dated 8 August 2023, 11 September 2023 and 12 September 2023 (the “**Announcements**”) in relation to the Rights Issue.
- 1.2. Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Announcements.

2. NOTICE OF RECORD DATE FOR THE RIGHTS ISSUE

- 2.1. **NOTICE IS HEREBY GIVEN** that the register of members and the share transfer books of the Company will be closed at **5.00 p.m. (Singapore time) on 3 October 2023** (the “**Record Date**”) for the purpose of determining the provisional allotments of the Rights Shares of the Entitled Shareholders (being Entitled Depositors and Entitled Scripholders) under the Rights Issue.
- 2.2. The Shares will trade on a “cum-rights” basis on the Catalist board of the SGX-ST up to 5.00 p.m. (Singapore time) on 29 September 2023. The Shares will trade on an “ex-rights” basis from 9.00 a.m. (Singapore time) on 2 October 2023 and any person who purchases Shares on and from 2 October 2023 will not be entitled to any provisional allotments of Rights Shares under the Rights Issue.

3. ELIGIBILITY TO PARTICIPATE IN THE RIGHTS ISSUE

- 3.1. Entitled Shareholders (being Entitled Depositors and Entitled Scripholders) will be entitled to participate in the Rights Issue and receive a copy of a notification letter (the “**OIS Notification Letter**”) containing instructions on how to access the Offer Information Statement which will be electronically disseminated for viewing, together with the appropriate application forms and accompanying documents at their respective Singapore addresses as maintained with the records of CDP or the Share Registrar, as the case may be.
- 3.2. Subject to the terms and conditions of the Offer Information Statement and the accompanying documents, Entitled Shareholders will be at liberty to accept in full or in part, decline, or otherwise renounce, or, in the case of Entitled Depositors only, trade (during the “nil-paid” rights trading period prescribed by the SGX-ST) their provisional allotments of Rights Shares and will be eligible to apply for Excess Rights Shares in excess of their provisional allotments under the Rights Issue.

Entitled Depositors

- 3.3. “**Entitled Depositors**” are Shareholders with Shares standing to the credit of their securities accounts with CDP as at 5.00 p.m. (Singapore time) on the Record Date, provided that such Entitled Depositors have registered addresses in Singapore with CDP as at the Record Date or if they have registered addresses outside Singapore, they have provided CDP with a

registered address in Singapore no later than 5.00 p.m. (Singapore time) on the date being three (3) market days (being a day on which the SGX-ST is open for trading in securities) prior to the Record Date.

- 3.4. Entitled Depositors will be provisionally allotted the Rights Shares on the basis of the number of Shares standing to the credit of their securities accounts as at 5.00 p.m. (Singapore time) on the Record Date.

Entitled Scripholders

- 3.5. “**Entitled Scripholders**” are Shareholders whose share certificates have not been deposited with CDP as well as transferees who have tendered to the Share Registrar registrable transfers of their Shares and the certificates relating thereto for registration up to the Record Date, provided that such Entitled Scripholders have registered addresses in Singapore with the Company as at the Record Date, or if they have registered addresses outside Singapore, they have provided the Share Registrar with a registered address in Singapore no later than 5.00 p.m. (Singapore time) on the date being three (3) market days (being a day on which the SGX-ST is open for trading in securities) prior to the Record Date.
- 3.6. Entitled Scripholders will have to submit duly completed and stamped transfers in respect of Shares not registered in the name of CDP, together with all relevant documents of title, so as to be received up to 5.00 p.m. (Singapore time) on the Record Date by the Share Registrar, in order to be registered to determine provisional allotments of Rights Shares.

Supplementary Retirement Scheme (“SRS”)

- 3.7. Entitled Shareholders who had purchased the Shares using their accounts opened with a SRS approved bank from which money may be withdrawn for, *inter alia*, payment of the Rights Shares and/or Excess Rights Shares (“**SRS Accounts**”) must use, subject to applicable SRS rules and regulations, monies standing to the credit of their respective SRS Accounts to pay for the acceptance of their Rights Shares and/or (if applicable) application for Excess Rights Shares.
- 3.8. Such Entitled Shareholders who wish to accept their provisional allotment of Rights Shares and, if applicable, apply for Excess Rights Shares using SRS monies, will need to instruct the relevant SRS approved banks in which such SRS members hold their SRS Accounts under the SRS, to subscribe for Rights Shares and, if applicable, apply for Excess Rights Shares, on their behalf in accordance with the procedures set out in the Offer Information Statement.

Central Provident Fund Investment Scheme (“CPFIS”)

- 3.9. Entitled Shareholders who had purchased the Shares using their Central Provident Fund (“**CPF**”) account savings under the CPFIS from which money may be withdrawn for, *inter alia*, payment of the Rights Shares and/or Excess Rights Shares (“**CPF Funds**”) must use, subject to applicable CPF rules and regulations, their respective CPF Funds to pay for the acceptance of their Rights Shares and/or (if applicable) application for Excess Rights Shares.
- 3.10. Such Entitled Shareholders who wish to accept their provisional allotment of Rights Shares and, if applicable, apply for Excess Rights Shares using CPF Funds, will need to instruct the relevant CPF approved agent banks in which such CPF members hold their CPF investment accounts, to subscribe for Rights Shares and, if applicable, apply for Excess Rights Shares, on their behalf in accordance with procedures set out in the Offer Information Statement.

Foreign Shareholders

- 3.11. For practical reasons and to avoid any violation of the relevant legislation applicable in countries other than Singapore, the Rights Shares will **NOT** be offered to Shareholders with registered addresses outside Singapore as at 5.00 p.m. (Singapore time) on the Record Date and who have not, by no later than 5.00 p.m. (Singapore time) on the date being three (3) market days (being a day on which the SGX-ST is open for trading in securities) prior to the Record Date,

provided to the Share Registrar or CDP, as the case may be, with registered addresses in Singapore for the service of notices and documents (“**Foreign Shareholders**”). The Rights Issue is only made in Singapore and the Offer Information Statement and/or its accompanying documents have not been and will **NOT** be despatched to Foreign Shareholders or to any jurisdiction outside Singapore. As Foreign Shareholders will not be entitled to participate in the Rights Issue, no provisional allotments of the Rights Shares will be made to Foreign Shareholders and no purported acceptance thereof or application by any Foreign Shareholders will be valid.

- 3.12. If it is practicable to do so, arrangements may, at the discretion of the Company, be made for the provisional allotments of Rights Shares which would otherwise have been provisionally allotted to Foreign Shareholders, to be sold “nil-paid” on the Catalist board of the SGX-ST as soon as practicable, after dealings in the provisional allotments of Rights Shares commence. Such sales may, however, only be effected if the Company, in its absolute discretion, determines that a premium can be obtained from such sales, after taking into account expenses to be incurred in relation thereto. The net proceeds from all such sales, after deduction of all expenses therefrom, will be dealt with in accordance with the terms set out in the Offer Information Statement.

4. OFFER INFORMATION STATEMENT

Further details of the Rights Issue will be made available in the Offer Information Statement to be electronically disseminated to Entitled Shareholders in due course, and appropriate announcements in relation to the lodgement and dissemination of the Offer Information Statement will be made.

5. CAUTIONARY STATEMENT

Shareholders and potential investors are advised to exercise caution when dealing or trading in the Shares. The completion of the Rights Issue is subject to certain conditions. As at the date of this announcement, there is no certainty or assurance that the Rights Issue will be completed or that no changes will be made to the terms thereof. Shareholders and potential investors are advised to read this announcement and any further announcements by the Company carefully and where in doubt as to the action they should take, they should consult their stockbrokers, bank managers, solicitors, accountants, tax advisers or other professional adviser(s) immediately.

BY ORDER OF THE BOARD

Lee Wei Hsiung
Company Secretary
21 September 2023

*This announcement has been prepared by Meta Health Limited (the “**Company**”) and its contents have been reviewed by the Company’s sponsor, ZICO Capital Pte. Ltd. (the “**Sponsor**”), in accordance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) Listing Manual Section B: Rules of Catalist.*

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Alex Tan, Chief Executive Officer, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.